Abstract
The present industry update covers the period 16 February–15 March 2012, which included the announcement of two large deals in the drug conjugation space – Mersana partnered its Fleximer technology with Endo for application to antibody drug conjugates, and Angiochem partnered with GlaxoSmithKline for application of its LRP-1 receptor-targeting technology to lysosomal storage diseases. Two Boston, MA, USA-area start-ups reached early funding milestones: 4s3 Bioscience, developing an antibody-based system for enhanced intracellular delivery of proteins, closed a US$20 million Series A round, while Kala Pharmaceuticals, developing a mucus-penetrating particle technology, completed a US$11.2 million seed round. Organogenesis’ cell-based mucogingival therapy and Discovery Labs’ synthetic peptide-based pulmonary surfactant received product approvals. Endocyte announced plans to submit marketing applications for its folate-receptor targeting-based diagnostic and therapy for ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
